NEW YORK – AstraZeneca has inked a deal with Jacobio Pharma for the exclusive rights to develop and commercialize the firm's pan-KRAS inhibitor outside of China. AstraZeneca is paying Jacobio $100 ...
NEW YORK – The convergence of gene-editing breakthroughs and new regulatory frameworks signaled a turning point in 2025 for getting gene therapies for rare diseases to patients. It's notoriously ...
Biomarker Therapy in 2025: More Lung Cancer Options, Competition in New Drug Classes, ctDNA Advances
This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing ...
Endometrial02, researchers want to see whether Enhertu can replace current standard-of-care chemotherapy for patients with HER2-expressing tumors.
NEW YORK – BioMarin has stopped developing the investigational BMN 349 for treating alpha-1 antitrypsin deficiency (AATD)-associated liver disease, the company announced in a regulatory filing this ...
The Recommended Uniform Screening Panel now includes DMD and MLD, which has implications for firms developing treatments for ...
While autologous therapies are mainstream in blood cancers, experts warn against overhyping allogeneic and in vivo approaches ...
The firm will share updated data and new analyses from its Phase III trial with the agency, which issued a complete response ...
The trial results support Tukysa-Herceptin-Perjeta as yet another option for breast cancer patients in the frontline ...
RheumaGen will use the funds to advance its therapeutic development program in celiac disease through preclinical proof of concept.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback